IOZK article on treatment attempts for glioblastoma in the specialist journal: "Austin Oncology Case Report"

The IOZK working group published a scientific article in the journal Austin Oncology Case Report. In this study, patients with glioblastoma were retrospectively examined in the context of individual treatment attempts—under tumor-specific immunomodulation using modulated electro-hyperthermia in combination with oncolytic virotherapy—in addition to chemotherapy with Temodal. The adjuvant therapy indicates a better therapeutic effect when immunological therapy, which induces immunogenic cell death of tumor cells, is performed in addition to chemotherapy. The biomarkers that indicate this were detected here.

The data suggest that combining hyperthermia and virotherapy during Temodal therapy clearly offers advantages in terms of improving overall survival. While chemotherapy treatment is only effective on dividing tumor cells, this additional method induces immunogenic cell death regardless of division.

• The Induction of Immunogenic Cell Death (ICD) During Maintenance Chemotherapy and Subsequent Multimodal Immunotherapy for Glioblastoma (GBM). Authors: Van Gool SW, Makalowski J, Feyen O, Prix L, Schirrmacher V, and Stuecker W.